UBS AM
GBT

UBS AM’s Global Blood Therapeutics, Inc. GBT Stock Holding History

UBS AM’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-244,631
Closed -$16.7M – 2811
2022
Q3 		$16.7M Sell
244,631
-165,292
-40% -$9.12M 0.01% 809
2022
Q2 		$13.1M Buy
409,923
+333,449
+436% +$9.76M 0.01% 854
2022
Q1 		$2.65M Buy
76,474
+1,349
+2% +$40.3K ﹤0.01% 1646
2021
Q4 		$2.2M Hold
75,125
– – ﹤0.01% 1826
2021
Q3 		$1.91M Buy
75,125
+854
+1% +$25.1K ﹤0.01% 1861
2021
Q2 		$2.6M Sell
74,271
-17,611
-19% -$688K ﹤0.01% 1732
2021
Q1 		$3.74M Buy
91,882
+2,370
+3% +$109K ﹤0.01% 1475
2020
Q4 		$3.88M Buy
89,512
+15,293
+21% +$754K ﹤0.01% 1398
2020
Q3 		$4.09M Buy
74,219
+1,958
+3% +$124K ﹤0.01% 1231
2020
Q2 		$4.56M Buy
72,261
+282
+0.4% +$19.3K ﹤0.01% 1151
2020
Q1 		$3.68M Buy
71,979
+5,806
+9% +$389K ﹤0.01% 1169
2019
Q4 		$5.26M Buy
66,173
+4,828
+8% +$286K ﹤0.01% 1167
2019
Q3 		$2.98M Buy
61,345
+11,909
+24% +$621K ﹤0.01% 1425
2019
Q2 		$2.6M Buy
49,436
+11,313
+30% +$650K ﹤0.01% 1459
2019
Q1 		$2.02M Sell
38,123
-1,537
-4% -$75.5K ﹤0.01% 1516
2018
Q4 		$1.63M Buy
39,660
+8,014
+25% +$300K ﹤0.01% 1524
2018
Q3 		$1.2M Buy
31,646
+705
+2% +$31.2K ﹤0.01% 1737
2018
Q2 		$1.4M Buy
30,941
+1,049
+4% +$47.8K ﹤0.01% 1673
2018
Q1 		$1.44M Buy
29,892
+5,881
+24% +$328K ﹤0.01% 1625
2017
Q4 		$945K Buy
24,011
+16,511
+220% +$617K ﹤0.01% 1774
2017
Q3 		$233K Hold
7,500
– – ﹤0.01% 2181
2017
Q2 		$205K Sell
7,500
-8,692
-54% -$259K ﹤0.01% 2214
2017
Q1 		$597K Buy
+16,192
New +$408K ﹤0.01% 1803

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

UBS AM's GBT Position: Q4 2022 in Review

UBS AM sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 244,631 shares — an estimated $16.7M sold.

UBS AM first reported a position in GBT in Q1 2017 and held it in 23 quarters. The position peaked at $16.7M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • UBS AM reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • UBS AM sold 244,631 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $16.7M.
  • UBS AM first reported a position in Global Blood Therapeutics, Inc. in Q1 2017 and held it in 23 quarters.
  • UBS AM's Global Blood Therapeutics, Inc. position peaked at $16.7M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on UBS AM's 13F filing for Q4 2022, filed 14 Feb 2023.